CD274 and neoplasm: Presented at ASCO 2022, the combination therapy showed improved tumor downstaging and a higher pCR rate (24% vs. 15%), especially in patients with higher PD-L1 expression (33% vs. 12% in CPS ≥10) and MSI-H tumors (63% vs. 27%).